Results 21 to 30 of about 11,258 (167)

Influence of BCR/ABL fusion proteins on the course of Ph leukemias.

Acta Biochimica Polonica, 2004
The hallmark of chronic myeloid leukemia (CML) and a subset of acute lymphoblastic leukemia (ALL) is the presence of the Philadelphia chromosome as a result of the t(9;22) translocation. This gene rearrangement results in the production of a novel oncoprotein, BCR/ABL, a constitutively active tyrosine kinase.
Gennady D, Telegeev, Anna N, Dubrovska, Mykhaylo V, Dybkov, Stanislav S, Maliuta   +3 more
openaire   +3 more sources

p185BCR/ABL has a lower sensitivity than p210BCR/ABL to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia

Haematologica, 2012
Background The t(9;22) translocation leads to the formation of the chimeric breakpoint cluster region/c-abl oncogene 1 (BCR/ABL) fusion gene on der22, the Philadelphia chromosome. The p185BCR/ABL or the p210BCR/ABL fusion proteins are encoded as a result
Afsar A. Mian, Anna Metodieva, Yousef Najajreh, Oliver G. Ottmann, Jamal Mahajna, Martin Ruthardt   +5 more
doaj   +1 more source

Translational regulation of GPx-1 and GPx-4 by the mTOR pathway.

PLoS ONE, 2014
Glutathione peroxidase activity was previously determined to be elevated in lymphocytes obtained from patients treated with the Bcr-Abl kinase inhibitor imatinib mesylate.
Emily N Reinke, Dede N Ekoue, Soumen Bera, Nadim Mahmud, Alan M Diamond   +4 more
doaj   +1 more source

Detection of derivative 9 deletion by BCR-ABL fluorescence in-situ hybridization signal pattern to evaluate treatment response in CML patients [PDF]

Archive of Oncology, 2009
Background: To evaluate prognostic effect of submicroscopic deletions involving breakage and fusion points of the derivative chromosome 9 and 22 in chronic myeloid leukemia in untreated patients and their follow up samples to correlate with disease ...
Bakshi Sonal R., Shah Pankaj M., Shukla Shilin N., Dalal Esha N., Iyer Ramesh R., Brahmbhatt Manisha M., Gajjar Sarju B., Trivedi Pina J., Patel Beena P.   +8 more
doaj   +1 more source

Flow Cytometric Detection of BCR-ABL Fusion Proteins in Leukemia Patients Via An Immunobead Assay [PDF]

Blood, 2008
Abstract The BCR-ABL fusion gene results from the translocation t(9;22). It is the hallmark of chronic myeloid leukemia (CML) and is present in a poor-risk subgroup of precursor B cell acute lymphoblastic leukemia (ALL), which represents 25–30% of adult ALL and 3–5% of childhood ALL.
Jacques JM van Dongen, Frank J.T. Staal, Elizabeth Macintyre, Tomas Kalina, Lukasz Sedek, Paulo Lucio, Juan Flores Montero, Elisabeth R. Van Wering, Nancy Boeckx, Sebastian Böttcher, Vincent H.J. Van der Velden, E. Dekking, Floor Weerkamp   +12 more
openaire   +1 more source

Tyrosine kinase chromosomal translocations mediate distinct and overlapping gene regulation events

BMC Cancer, 2011
Background Leukemia is a heterogeneous disease commonly associated with recurrent chromosomal translocations that involve tyrosine kinases including BCR-ABL, TEL-PDGFRB and TEL-JAK2. Most studies on the activated tyrosine kinases have focused on proximal
Kim Hani, Gillis Lisa C, Jarvis Jordan D, Yang Stuart, Huang Kai, Der Sandy, Barber Dwayne L   +6 more
doaj   +1 more source

The tyrosine phosphatase TC48 interacts with and inactivates the oncogenic fusion protein BCR-Abl but not cellular Abl

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2013
The chimeric oncoprotein BCR-Abl exhibits deregulated protein tyrosine kinase activity and is responsible for the pathogenesis of certain human leukemias, such as chronic myelogenous leukemia. The activities of cellular Abl (c-Abl) and BCR-Abl are stringently regulated and the cellular mechanisms involved in their inactivation are poorly understood ...
Mitra, Aninda, Sasikumar, Kotagiri, Parthasaradhi, B.V.V., Radha, Vegesna   +3 more
openaire   +2 more sources

Co-existence of AML1-ETO and BCR-ABL1 transcripts in a relapsed patient of acute myeloid leukemia with favorable risk group: A coincidence or clonal evolution?

Hematology/Oncology and Stem Cell Therapy, 2017
Prognosis of acute myeloid leukemia relies heavily on the cytogenetic and molecular abnormalities. AML1-ETO fusion protein resulting from t(8;21), a recurring cytogenetic abnormality, is known to be associated with favorable prognosis.
Manish K. Singh, Ruchi Gupta, Khaliqur Rahman, Sanjeev Kumar, Akhilesh Sharma, Soniya Nityanand   +5 more
doaj   +1 more source

Two different point mutations in ABL gene ATP-binding domain conferring Primary Imatinib resistance in a Chronic Myeloid Leukemia (CML) patient: A case report

Biological Procedures Online, 2004
Imatinib (Gleevec) is the effective therapy for BCR-ABL positive CML patients. Point mutations have been detected in ATP-binding domain of ABL gene which disturbs the binding of Gleevec to this target leading to resistance.
Iqbal Zafar, Siddiqui Rubina T., Qureshi Javed A.   +2 more
doaj   +1 more source

Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myleoid Leukemia: Comparison with FISH and PCR Techniques.

PLoS ONE, 2015
Chronic Myeloid Leukemia (CML) is characterized by a balanced translocation juxtaposing the Abelson (ABL) and breakpoint cluster region (BCR) genes.
Anna Grazia Recchia, Nadia Caruso, Sabrina Bossio, Mariavaleria Pellicanò, Laura De Stefano, Stefania Franzese, Angela Palummo, Vincenzo Abbadessa, Eugenio Lucia, Massimo Gentile, Ernesto Vigna, Clementina Caracciolo, Antolino Agostino, Sara Galimberti, Luciano Levato, Fabio Stagno, Stefano Molica, Bruno Martino, Paolo Vigneri, Francesco Di Raimondo, Fortunato Morabito   +20 more
doaj   +1 more source